Biotech · Public company · South San Francisco, CA, US

Vaxart, Inc.

Ticker VXRT · SEC CIK 0000072444

Track this companyFree. Adds Vaxart, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials121 recruiting or active

Pipeline programs18From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline18

Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dosePhase 2 · Norovirus InfectionsClinicalTrials.gov · fetched Nov 12, 2026
Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power 11 IU/dosePhase 2 · Norovirus InfectionsClinicalTrials.gov · fetched Nov 12, 2026
COMIRNATY®Phase 2 · SARS-CoV2ClinicalTrials.gov · fetched Nov 12, 2026
Fluzone®Phase 2 · InfluenzaClinicalTrials.gov · fetched Nov 12, 2026
Norovirus GI.1 Norwalk Virus InoculumPhase 2 · Norovirus InfectionsClinicalTrials.gov · fetched Nov 12, 2026
Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dosePhase 2 · Norovirus InfectionsClinicalTrials.gov · fetched Nov 12, 2026
VXA-A1.1Phase 2 · InfluenzaClinicalTrials.gov · fetched Nov 12, 2026
VXA-CoV2-1.1-SPhase 2 · COVID-19ClinicalTrials.gov · fetched Nov 12, 2026
VXA-CoV2-3.1Phase 2 · SARS-CoV2ClinicalTrials.gov · fetched Nov 12, 2026
VXA-CoV2-3.3Phase 2 · SARS-CoV2ClinicalTrials.gov · fetched Nov 12, 2026
VXA-G1.1-NNPhase 2 · Norovirus InfectionsClinicalTrials.gov · fetched Nov 12, 2026
VXA G1.1 NN-TPhase 1 · Norovirus InfectionsClinicalTrials.gov · fetched Nov 12, 2026
VXA G2.4 NS-TPhase 1 · Norovirus InfectionsClinicalTrials.gov · fetched Nov 12, 2026
VXA-CoV2-1Phase 1 · Covid19ClinicalTrials.gov · fetched Nov 12, 2026
VXA-G1.1-NNPhase 1 · Norovirus InfectionClinicalTrials.gov · fetched Nov 12, 2026
VXA-G2.4-NSPhase 1 · Norovirus InfectionClinicalTrials.gov · fetched Nov 12, 2026
VXA-G2.4-NSPhase 1 · Norovirus InfectionsClinicalTrials.gov · fetched Nov 12, 2026
VXA-GI.1.NNPhase 1 · Norovirus InfectionsClinicalTrials.gov · fetched Nov 12, 2026

Clinical trials12

A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years OldPHASE1 · COMPLETED · started Mar 3, 2025ClinicalTrials.gov NCT06944717 · fetched Nov 12, 2026
A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 InfectionPHASE2 · ACTIVE_NOT_RECRUITING · started Oct 8, 2024ClinicalTrials.gov NCT06672055 · fetched Nov 12, 2026
A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy VolunteersPHASE2 · COMPLETED · started Jan 26, 2023ClinicalTrials.gov NCT05626803 · fetched Nov 12, 2026
A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult VolunteersPHASE1 · COMPLETED · started Jan 24, 2022ClinicalTrials.gov NCT05213728 · fetched Nov 12, 2026
Norovirus Challenge StudyPHASE1_PHASE2 · COMPLETED · started Dec 27, 2021ClinicalTrials.gov NCT05212168 · fetched Nov 12, 2026
A Ph 2 Trial With an Oral Tableted COVID-19 VaccinePHASE2 · TERMINATED · started Oct 22, 2021ClinicalTrials.gov NCT05067933 · fetched Nov 12, 2026
Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus VaccinesPHASE1_PHASE2 · COMPLETED · started Apr 30, 2021ClinicalTrials.gov NCT04875676 · fetched Nov 12, 2026
Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus VaccinePHASE1 · COMPLETED · started Apr 26, 2021ClinicalTrials.gov NCT04854746 · fetched Nov 12, 2026
Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of SubjectsPHASE1 · COMPLETED · started Sep 21, 2020ClinicalTrials.gov NCT04563702 · fetched Nov 12, 2026
Safety & Immunogenicity Study of Ad5 Based Oral Norovirus VaccinesPHASE1 · COMPLETED · started Mar 20, 2019ClinicalTrials.gov NCT03897309 · fetched Nov 12, 2026
Evaluation of Infectivity and Illness of Norwalk GI.1 Virus Lot 001-09NV in the Human Challenge ModelPHASE1 · COMPLETED · started Oct 3, 2018ClinicalTrials.gov NCT03721549 · fetched Nov 12, 2026
A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu VaccinePHASE2 · COMPLETED · started Aug 31, 2016ClinicalTrials.gov NCT02918006 · fetched Nov 12, 2026

SEC filings12

10-Q · FORM 10-QSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
8-K · FORM 8-KSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
8-K · FORM 8-KSEC EDGAR · filed Oct 19, 2026 · fetched Nov 12, 2026
8-K · FORM 8-KSEC EDGAR · filed Sep 14, 2026 · fetched Nov 12, 2026
8-K · FORM 8-KSEC EDGAR · filed Aug 25, 2026 · fetched Nov 12, 2026
10-Q · FORM 10-QSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
8-K · FORM 8-KSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
8-K · FORM 8-KSEC EDGAR · filed Jul 28, 2026 · fetched Nov 12, 2026
8-K · FORM 8-KSEC EDGAR · filed Jul 17, 2026 · fetched Nov 12, 2026
8-K · FORM 8-KSEC EDGAR · filed Jul 7, 2026 · fetched Nov 12, 2026
8-K · CURRENT REPORTSEC EDGAR · filed Jul 2, 2026 · fetched Nov 12, 2026
8-K · FORM 8-KSEC EDGAR · filed Jun 26, 2026 · fetched Nov 12, 2026